Video Report: Genentech Defends Its Position on Avastin

On the second day of the Avastin hearing at the Food and Drug Administration, Genentech officials took the podium and in a two-hour session argued why Avastin should be approved for metastatic breast cancer.

On the second day of the Avastin hearing at the Food and Drug Administration, Genentech officials took the podium and in a two-hour session argued why Avastin should be approved for metastatic breast cancer.

On the second day of the Avastin hearing at the Food and Drug Administration, Genentech officials took the podium and in a two-hour session argued why Avastin should be approved for metastatic breast cancer.